The latest Crystal Reports dated December 13th, 2012 for NVIV is an outstanding document that is quite informative. It will answer a whole host of questions and even clarifies certain points that all longer termed investors may not fully be aware of. Excellent and definitely reassuring. If you can handle the ups and downs and the frustrating delays, I believe all will be well served investing here.
Great probability that by March or sooner (as with the HUD) that FDA will have granted both the HUD and the IDE approvals and human trials ready to roll.
Geisinger peripheral study should be done and reported. This would boost the prospects of the first hydrogel product in terms of demonstrating safety and efficacy as well as speeding up its time to market.
Getting in or expanding shares now under $3 is a great buy, as these days are numbered.
good post, looks like today is one those bio selloff days, most all that i track are red. I'm very excited about NVIV future, I rate it as the riskier of the bio's I hold but one that could skyrocket well over $10 quickly if current schedules are met and turn out positive. An obvious buyout candidate by a larger pharma if their trials are successful. I like their multi-tiered approach but they need to get the ball rolling soon, others are trying to solve this tragedy also. My other bio's, AMRN, ARNA (good long term holds with sales to start within weeks- potential bil$$ drugs), and ATRS (lots going on here and already in bed with multiple big pharma, probably the safest play I have). All imo, and glta